Dynamic structural determinants underlie the neurotoxicity of the N-terminal tau 26-44 peptide in Alzheimer's disease and other human tauopathies.


Journal

International journal of biological macromolecules
ISSN: 1879-0003
Titre abrégé: Int J Biol Macromol
Pays: Netherlands
ID NLM: 7909578

Informations de publication

Date de publication:
01 Dec 2019
Historique:
received: 24 05 2019
revised: 10 08 2019
accepted: 26 08 2019
pubmed: 31 8 2019
medline: 1 5 2020
entrez: 31 8 2019
Statut: ppublish

Résumé

The intrinsically disordered tau protein plays a pivotal role in the pathogenesis of Alzheimer's disease (AD) and other human tauopathies. Abnormal post-translational modifications of tau, such as truncation, are causally involved in the onset/development of these neurodegenerative diseases. In this context, the AD-relevant N-terminal fragment mapping between 26 and 44 amino acids of protein (tau26-44) is interesting, being endowed with potent neurotoxic effects in vitro and in vivo. However, the understanding of the mechanism(s) of tau26-44 toxicity is a challenging task because, similarly to the full-length tau, it does not have a unique 3D structure but exists as dynamic ensemble of conformations. Here we use Atomic Force Spectroscopy, Small Angle X-ray Scattering and Molecular Dynamics simulation to gather structural and functional information on the tau26-44. We highlight the presence, the type and the location of its temporary secondary structures and we unveil the occurrence of relevant transient tertiary conformations that could contribute to tau26-44 toxicity. Data are compared with those obtained on the biologically-inactive, reverse-sequence (tau44-26 peptide) which has the same mass, charge, aminoacidic composition as well as the same overall unfolded character of tau26-44.

Identifiants

pubmed: 31470053
pii: S0141-8130(19)33861-9
doi: 10.1016/j.ijbiomac.2019.08.220
pii:
doi:

Substances chimiques

Peptides 0
tau Proteins 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

278-289

Informations de copyright

Copyright © 2019. Published by Elsevier B.V.

Auteurs

Giordano Perini (G)

Istituto di Fisica, Università Cattolica del Sacro Cuore, Roma, Italy; Fondazione Policlinico A. Gemelli IRCCS, Roma, Italy.

Gabriele Ciasca (G)

Istituto di Fisica, Università Cattolica del Sacro Cuore, Roma, Italy; Fondazione Policlinico A. Gemelli IRCCS, Roma, Italy. Electronic address: gabriele.ciasca@unicatt.it.

Eleonora Minelli (E)

Istituto di Fisica, Università Cattolica del Sacro Cuore, Roma, Italy; Fondazione Policlinico A. Gemelli IRCCS, Roma, Italy.

Massimiliano Papi (M)

Istituto di Fisica, Università Cattolica del Sacro Cuore, Roma, Italy; Fondazione Policlinico A. Gemelli IRCCS, Roma, Italy.

Valentina Palmieri (V)

Istituto di Fisica, Università Cattolica del Sacro Cuore, Roma, Italy; Fondazione Policlinico A. Gemelli IRCCS, Roma, Italy.

Giuseppe Maulucci (G)

Istituto di Fisica, Università Cattolica del Sacro Cuore, Roma, Italy; Fondazione Policlinico A. Gemelli IRCCS, Roma, Italy.

Matteo Nardini (M)

Istituto di Fisica, Università Cattolica del Sacro Cuore, Roma, Italy; Fondazione Policlinico A. Gemelli IRCCS, Roma, Italy.

Valentina Latina (V)

European Brain Research Institute (EBRI), Viale Regina Elena 295, 00161 Rome, Italy.

Veronica Corsetti (V)

European Brain Research Institute (EBRI), Viale Regina Elena 295, 00161 Rome, Italy.

Fulvio Florenzano (F)

European Brain Research Institute (EBRI), Viale Regina Elena 295, 00161 Rome, Italy.

Pietro Calissano (P)

European Brain Research Institute (EBRI), Viale Regina Elena 295, 00161 Rome, Italy.

Marco De Spirito (M)

Istituto di Fisica, Università Cattolica del Sacro Cuore, Roma, Italy; Fondazione Policlinico A. Gemelli IRCCS, Roma, Italy.

Giuseppina Amadoro (G)

European Brain Research Institute (EBRI), Viale Regina Elena 295, 00161 Rome, Italy; Institute of Translational Pharmacology (IFT)-CNR, Via Fosso del Cavaliere 100, 00133 Rome, Italy. Electronic address: g.amadoro@inmm.cnr.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH